Despite advances in our understanding of the molecular basis for particular subtypes of acute myeloid leukemia (AML), effective therapy remains a challenge for many individuals suffering from this disease. A significant proportion of both pediatric and adult AML patients cannot be cured and since the upper limits of chemotherapy intensification have been reached, there is an urgent need for novel therapeutic approaches. The transcription factor c-MYB has been shown to play a central role in the development and progression of AML driven by several different oncogenes, including mixed lineage leukemia (MLL)-fusion genes. Here, we have used a c-MYB gene expression signature from MLL-rearranged AML to probe the Connectivity Map database and identified mebendazole as a c-MYB targeting drug. Mebendazole induces c-MYB degradation via the proteasome by interfering with the heat shock protein 70 (HSP70) chaperone system. Transient exposure to mebendazole is sufficient to inhibit colony formation by AML cells, but not normal cord blood-derived cells. Furthermore, mebendazole is effective at impairing AML progression in vivo in mouse xenotransplantation experiments. In the context of widespread human use of mebendazole, our data indicate that mebendazoleinduced c-MYB degradation represents a safe and novel therapeutic approach for AML.
INTRODUCTION
Rational combination of intensive chemotherapy with risk stratification has revolutionized the treatment of acute leukemia in children. However, progress has not been uniform across all subtypes of disease and many pediatric 1 and adult 2 acute myeloid leukemia (AML) patients cannot be cured by current therapies. It is widely accepted that further intensification of chemotherapy is unlikely to improve outcomes, 3, 4 but that this may be achieved by developing novel therapeutics targeting specific leukemia drugsusceptibilities.
Rearrangements of the MLL gene are often associated with AML in children, and less frequently in adults. 5 These abnormalities result in generation of MLL fusion proteins, which are responsible for driving development of the disease. These proteins hijack the normal epigenetic machinery in developing hematopoietic cells, enforcing transcriptional dysregulation of target genes. [6] [7] [8] [9] Identification of components of the MLL fusion-associated complexes led to a number of drug discovery initiatives. 10, 11 Recent studies indicate that one transcriptional target in particular, encoding the transcription factor c-MYB, is responsible for maintaining aberrant hematopoietic self-renewal programs necessary for initiation and progression of MLL-rearranged AML. [12] [13] [14] [15] c-MYB is highly expressed in immature hematopoietic progenitor cells and is required for definitive hematopoiesis, 16 normal myelopoiesis 17 and maintenance of adult hematopoietic stem cell self-renewal. 18 c-MYB is rarely mutated in human leukemia, but has long been associated with hematopoietic malignancies. 19, 20 Some leukemia cells have been shown to be more sensitive to c-MYB inhibition than normal hematopoietic cells. 21, 22 This led to the hypothesis that although it may not be an oncogenic driver itself, certain cancers are nevertheless 'addicted' transcriptional dysregulation by c-MYB. 23 In contrast to absolute c-MYB deficiency, low levels of c-MYB expression are compatible with limited hematopoiesis, especially myelopoiesis, 15, 24 suggesting that a window may exist for therapeutic targeting of c-MYB in AML. However, difficulties associated with developing small molecule inhibitors of transcription factor activity suggest that alternative approaches may be required to target c-MYB. 19 For example, the interaction between c-MYB and the transcriptional co-activator p300 was recently shown to be essential for AML induction 25 and to have promising potential as a target for pharmacological inhibition. 26 In order to identify bioactive compounds capable of inhibiting c-MYB transcriptional activity in AML, we screened the Connectivity Map (CMAP) database with a c-MYB gene expression signature derived from integrating MLL-fusion protein-specific gene expression changes with a list of previously published direct c-MYB target genes. 27, 28 This analysis identified the anti-helminth drug mebendazole as the top hit. We demonstrate that mebendazole induces proteasomal degradation of c-MYB, inhibits AML cell selfrenewal and impairs AML progression in vivo. This work demonstrates that mebendazole has excellent potential for repurposing in novel AML therapies.
MATERIALS AND METHODS Mice
Mice were maintained in the UCL GOSICH animal facilities and experiments were performed according to and approved by the United Kingdom Home Office regulations and followed UCL GOSICH institutional guidelines.
Human samples
For human AML samples (Supplementary Table 1 Global gene expression, SPIEDw and gene set enrichment (GSEA) analyses Analysis of MLL-ENL/MLL-AF9 gene expression changes (Geo repository: GSE59236) was performed using Affymetrix arrays (Affymetrix UK, High Wycombe, UK) and conditionally immortalized MLL-ENL and MLL-AF9 mouse myeloid cells. [29] [30] [31] [32] Gene expression changes resulting from 6 h exposure of THP1 cells to 10 μM mebendazole or DMSO were analyzed by RNA-sequencing (Geo repository: GSE96544). A list (Supplementary Table  2 ) of human orthologs of MLL-ENL/MLL-AF9 gene expression changes, for genes also contained in the list of 1063 genes bound by c-MYB in mouse myeloid ERMYB cells 27 and deregulated in THP1 cells following siRNAmediated c-MYB silencing, 28 were used to interrogate the CMAP database (https://portals.broadinstitute.org/cmap/) 33 using the SPIEDw web tool 34 (http://www.spied.org.uk/). For GSEA, c-MYB signatures were derived from Zhao et al. 27 and leukemia stem cell (LSC) signatures from Somervaille et al.
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Cell culture and reagents Human AML cell lines were purchased from the ATCC (THP1) and DSMZ (OCI-AML3, NOMO-1, KCL22, U937, MV4;11, KASUMI-1 and SHI-1), authenticated by short tandem repeat profiling using the PowerPlex 16 system (Promega, Southampton, UK) and mycoplasma negative status confirmed using the MycoAlert Mycoplasma Detection Kit (Lonza, Verviers, Belgium). 293FT cells were from ThermoFisher Scientific (ThermoFisher Scientific, Hemel Hempstead, UK) and immortalized mouse myeloid cells were cultured as previously described. [29] [30] [31] [32] Colony formation assays AML 
In vivo transplantation
Luciferase expressing THP1 cells were transplanted into non-irradiated NOD-SCID-γ − / − (NSG; The Jackson Laboratory, Bar Harbor, ME, USA) mice. Recipient mice were imaged using the IVIS Lumina Series III (PerkinElmer, Beaconsfield, UK) and randomly allocated to control or mebendazoletreated groups. Mebendazole (200 mg/kg of diet) was administered ad libitum in regular powdered diet, changed daily.
Lentivirus vector cloning
The ΔMYB cDNA 35 was cloned into the pCSGW-PIG vector, made by replacing the GFP cDNA from pCSGW 36 with a puro-IRES-GFP cassette. catalogue number sc-24, Santa Cruz Biotechnology), Actin (I-19, catalogue number sc-1616, Santa Cruz Biotechnology), β-Actin (C4, catalogue number sc-47778, Santa Cruz Biotechnology), αTubulin (YL1/2, catalogue number sc-53029, Santa Cruz Biotechnology), SP1 (PEP 2, catalogue number sc-59, Santa Cruz Biotechnology).
Microtubule depolymerization assay
Microtubule depolymerization was analyzed as published previously. 37 Quantitative RT-PCR analysis Quantitative RT-PCR (qPCR) was performed on isolated mRNA using TaqMan probe based chemistry and an ABI Prism 7900HT fast Sequence Detection System (Life Technologies, Paisley, UK). All primer/probe sets were from Applied Biosystems, Life Technologies (Applied Biosystems Inc, Foster City, CA, USA).
Statistics
Statistical significance was determined using Prism (GraphPad) software. Statistical analysis of survival curves was performed using the MantelHaenszel log-rank test. Statistical analysis of means was performed using the one sample t-test or unpaired Student's t-test, two-tailed P-values o 0.05 being considered statistically significant. Variance was similar between groups.
Further details are provided in Supplementary Materials and Methods.
RESULTS
To identify candidate anti-leukemia drugs, we generated a therapeutic signature (Supplementary Table 2 ) by integrating Figure 3) .
gene expression changes due to MLL fusion silencing [29] [30] [31] [32] with transcriptional regulation by c-MYB in AML. 27, 28 This signature was then used to interrogate drug-induced gene expression profiles in the CMAP database 33 using the SPIEDw web tool 34 ( Figure 1a) . The top hit resulting from this analysis was the anti-helminth agent mebendazole (Figure 1b) .
In order to determine whether mebendazole was able to interfere with c-MYB-regulated transcriptional pathways in human AML cells, RNASeq was performed on the MLL-AF9 expressing cell line THP1, following short-term exposure to the drug. GSEA of mebendazole-induced gene expression changes confirmed that this drug was able to reverse both activation and repression by c-MYB of its target genes (Figure 1c and Supplementary Figure 1) . Mebendazole exhibited anti-leukemia activity against MLL rearranged and non-rearranged human AML cell lines (Figure 2a and Supplementary Figure 2) and was effective at blocking their colony forming activity (Figure 2b and Supplementary Figure 3) . This is not surprising, since c-MYB has also been shown to play a critical function in non-rearranged subtypes of AML. 25, 26, [38] [39] [40] [41] Indeed, shRNA-mediated silencing of c-MYB expression had a severe impact on colony formation (Supplementary Figure 4) .
We then examined whether mebendazole interfered with c-MYB-regulated gene expression by targeting the transcription factor directly, by examining RNA and protein expression 6 h after exposure of AML cells to the drug. Interestingly, mebendazole inhibited c-MYB protein expression in all cell lines examined, and RNA expression in some (Figure 3a) . c-MYB protein expression was affected at lower concentrations of mebendazole than those required to inhibit RNA expression, and occurred without any change in RNA expression in some cells, suggesting that mebendazole targets c-MYB expression primarily at the protein level. Indeed, reversal of c-MYB protein loss by proteasomal inhibition indicates that mebendazole targets c-MYB for proteasomal degradation (Figure 3b and Supplementary Figure 5) .
There has been considerable interest recently in repurposing mebendazole for cancer therapy. 42 However, the mechanism for its anti-cancer activity has remained elusive. Initially this was thought to derive from its microtubule destabilizing activity, mebendazole binding tubulin at the colchicine-site, 43 although recent experiments have suggested alternative mechanisms. 44 We compared microtubule depolymerization and c-MYB degradation induced by mebendazole in AML cells to that resulting from treatment of the cells with the microtubule disrupting agent Exactly how mebendazole induces c-MYB degradation is unclear. It does not appear to be a secondary consequence of a cell cycle block, since c-MYB loss is already evident in THP1 cells after 4 h mebendazole exposure, prior to drug-induced changes in cell cycle profiles (Supplementary Figure 7) . In order to address this question, nematic protein organization technique analysis (Inoviem Scientific) of mebendazole was performed using cell lysates from a primary AML patient sample and THP1 cells (Supplementary Figures 8a and b) . DAVID analysis of the proteins identified in the AML patient sample hetero-assemblies, induced by mebendazole, highlighted 'protein folding' as the second most significant functional category, with 12 of the 16 proteins in this category also identified in THP1 hetero-assemblies (Supplementary Figure 8c) . This suggests that mebendazole disrupts the cellular protein folding machinery leading to the proteasomal targeting of c-MYB (Figure 3b ). Of particular interest were a number of proteins of the HSP70/HSP90 chaperone complexes. c-MYB has previously been shown to be an HSC70 client protein in prostate cancer cells. 45, 46 Indeed, we found that the HSP70/HSC70 chaperone complex is also associated with c-MYB in AML cells (Figure 4b and Supplementary Figure 9a) , an association that was lost upon exposure to mebendazole (Figure 4c) . Furthermore, HSPA1A knockdown and pharmacological HSP70 inhibition resulted in reduced c-MYB protein levels (Figure 4d and Supplementary Figures 9b and c) . However, mebendazole did not induce any changes in expression levels or subcellular re-localization of the HSP70/HSC70 complex (Supplementary Figure 9d) .
Since c-MYB has been placed at the center of a LSC transcriptional self-renewal program in MLL-rearranged leukemia, 13 we hypothesized that mebendazole treatment of MLL-rearranged AML cells would inhibit this program. Indeed, GSEA analysis of gene expression changes following treatment of THP1 cells with mebendazole demonstrated negative enrichment of the LSC self-renewal signature (Figure 5a ). In order to examine whether short-term exposure to mebendazole would indeed compromise AML cell self-renewal, we treated THP1 cells with 10 μM mebendazole for 16 h, washed them and examined their colony forming potential in vitro. Consistent with the observed inhibition of the LSC self-renewal program, transient exposure to mebendazole resulted in a more than 80% reduction in colony formation by THP1 cells (Figure 5b ). Our hypothesis predicts that stabilization of the c-MYB protein would have the potential to rescue this loss of self-renewal induced by mebendazole. In order to examine this possibility, we generated a C-terminal deletion mutant of c-MYB (ΔMYB), previously shown to result in enhanced protein stability, 35 and expressed this mutant in THP1 cells. ΔMYB was partially protected from mebendazole-induced degradation (Figure 5c ). Since the mutant contained the unaltered DNAbinding domain, which is necessary for the transcriptional activity of c-MYB, but which contains residues known to be targeted by ubiquitin-mediated proteasomal degradation, 47 it is not surprising that it was not completely resistant to mebendazole. However, ΔMYB expressing THP1 cells were found to express higher levels of total c-MYB protein than control THP1 cells, following 6 h treatment with mebendazole ( Figure 5c ). Importantly, this partial rescue of c-MYB protein expression correlated with increased colony forming potential of ΔMYB expressing THP1 cells following transient exposure to mebendazole (Figure 5d ). These data indicate that mebendazole inhibits AML colony formation by disrupting the c-MYB regulated LSC self-renewal program.
Interestingly, transient mebendazole exposure also inhibited in vitro colony formation by two independent MLL-AF9 expressing primary AML patient samples, but had no significant effect on colony formation by normal CD34
+ cord blood cells (Figure 5e and Supplementary Figure 10) . Interestingly, mebendazole only caused partial loss of c-MYB in the latter (Supplementary Figure 11) .
Having shown the anti-leukemia activity of mebendazole in vitro, we decided to test whether it could make an impact on AML disease progression in vivo. Oral administration of mebendazole, by simply mixing the drug in the diet, was found to have significant activity against disease in THP1 transplanted NSG mice, inhibiting leukemia progression (Figures 6a and b) and prolonging survival of treated mice (Figure 6c) . Interestingly, THP-1 cells isolated from mebendazole-treated mice were found to express increased c-MYB protein levels and to be more resistant to drug treatment (Supplementary Figure 12) . These data indicate that oral administration of mebendazole is sufficient to significantly impair AML progression in vivo.
DISCUSSION
Our data show that mebendazole induces degradation of the transcription factor c-MYB. c-MYB is essential for survival and selfrenewal of multiple AML subtypes. c-MYB degradation results in loss of AML cell viability, colony formation and impaired in vivo leukemia progression. The rescue of AML cells from the inhibition of colony formation, following transient exposure to mebendazole, by overexpression of the ΔMYB mutant highlights the significance of c-MYB degradation in the anti-AML effects of this drug. Although the ΔMYB mutant exhibits enhanced protein stability, 35 it is not completely resistant to mebendazole induced degradation, potentially explaining why the rescue of colony formation is only partial. It is likely that mebendazole interferes with multiple pathways in cancer cells 44 and it has been suggested to be a promising candidate for anti-cancer drug repurposing. 42 However, the induction of c-MYB degradation by mebendazole makes it particularly suitable to repurposing into AML therapy.
Some solid cancers are also addicted to continued and relatively high expression of the oncoprotein c-MYB. This is particularly evident in colorectal cancer where c-MYB is overexpressed and essential to continued proliferation and tumor cell survival. 19 In a recent study, mebendazole showed activity in the majority of the colon cancer cell lines tested. 44 It is noteworthy that a patient with refractory metastatic colon cancer treated with mebendazole showed near complete remission of the metastases in the lungs and lymph nodes and a good partial remission in the liver. 48 This suggests that mebendazole induced proteolysis of c-MYB may also have major clinical implications outside of AML therapy, in the treatment of a variety of cancers.
Induction of c-MYB degradation by mebendazole is blocked by proteasomal inhibition and occurs at much lower concentrations than those necessary to achieve microtubule depolymerization in AML cells. We present evidence for the involvement of the HSP70/ HSC70 chaperone complex in c-MYB targeting by mebendazole. The complex was found to bind c-MYB in AML cells, an association that was lost upon exposure of cells to mebendazole. Pharmacological or shRNA directed inhibition of HSP70 also resulted in loss of c-MYB protein. Interestingly, the HSP70/HSC70 complex has previously been shown to interact with c-MYB in prostate cancer cells, its displacement form the complex by glioma pathogenesisrelated protein 1 (GLIPR1) overexpression resulting in c-MYB protein destabilization. 45, 46 In summary, we have used Connectivity Map analysis to identify mebendazole as a novel candidate anti-AML therapeutic. Our data highlight a hitherto unappreciated link between microtubule interacting agents and the regulation of c-MYB protein degradation. Importantly, widespread use of mebendazole is tolerated in children and adults across the world, 49 suggesting that this drug has real potential for safe use in the treatment of human AML.
